Although RAS (i.e. N-RAS or K-RAS) gene mutations were only found in no more than 10% of AML cases, activation of RAS pathway by mutations in upstream receptors, e.g. FLT3 and c-KIT, or downstream effectors, broadly exist in AML45. This evidence concerns the gene KIT and acute myeloid leukemia.